News Releases

Synlogic Announces Closing of $21.0 Million Underwritten Public Offering

Synlogic Announces Pricing of $21.0 Million Underwritten Public Offering

Synlogic Announces Publication of Synpheny-1 Phase 2 Study of Synthetic Biotic for Phenylketonuria in Nature Metabolism

Synlogic Announces Reverse Stock Split

Synlogic to Participate in Chardan’s Genetic Medicines Conference

Synlogic Announces CEO Aoife Brennan Named to PharmaVoice 100

Synlogic Reports Second Quarter 2023 Financial Results and Provides Business Update

Synlogic Granted Fast Track Designation from FDA for labafenogene marselecobac (SYNB1934) for Treatment of Phenylketonuria

Synlogic Announces International Nonproprietary Name Selection for SYNB1934

Synlogic Announces Participation in SVB Securities Healthcare Therapeutics Forum

Synlogic Reminds Stockholders of 2023 Annual General Meeting Details

Synlogic Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of Phenylketonuria

Synlogic Therapeutics